Molecular biology; adipocyte development; regulation of adipogenesis by retinoblastoma proteins.
Our research investigates the effects of nutrition, body composition and physical activity on growth and metabolism of infants and children. Our multi-disciplinary group addresses complex questions regarding the interaction of these variables while considering multiple facets of child development. Major research projects currently investigate the consequences of prenatal environment and early infant feeding. Other projects also examine how to optimize nutrition and physical activity to improve overall health.
The lab studies the role of DNases in tissue injury and cell death.
Age Related Macular Degeneration (AMD), an eye disease which can cause loss of central vision in the population over the age of 50. Our laboratory is studying the Molecular and Biochemical mechanisms of AMD and uvietis in order to find a cure and/or prevention of the diseases.
As a pathologist and epidemiologist, I have broad interests in chronic diseases with a particular interest in the methodological issues facing observational and clinical studies. Specific interests include indicators of arteriosclerosis severity and vascular aging, gene-environmental interactions, orthostatic hypotension, stroke, the relationship between alcohol and cardiovascular disease, and novel vascular risk factors in renal disease.
Our goal is to develop antibody-based medications for stimulant abuse, which alter the pharmacokinetic properties of these drugs. These studies are part of a multidisciplinary, clinician scientist approach to the rational development of therapeutic strategies, and provide the background information necessary for translational research of the efficacy of antibody-based medications for the treatment of human drug abuse.
Radiation and Cancer biology, exosomes and cell to cell crosstalk in stem cell differentiation and activity, nanomedicine applications. Dr. Griffin’s research interests include: molecular and physiological mechanisms of radiation and thermal sensitization; modulation of tumor blood flow, angiogenesis and oxygenation; biology and physiology of thermal therapy; and oxygen partial pressure as predictor of cancer treatment response.
By understanding how the healthy brain encodes cognition, Dr. James seeks to translate this technology into patient care and better inform clinical decision-making. Dr. James believes that understanding individual differences in the neural encoding of traits such as craving, impulsivity, and working memory are crucial for understanding how these brain-behavior relationships are disrupted with addiction.
Dr. Laura James is Principal Investigator for the Pediatric Pharmacology Research Unit at Arkansas Children’s Hospital. Her research emphasis in the basic sciences is in understanding mechanisms of repair for hepatotoxins (acetaminophen, chloroform) in the mouse model. She is also interested in the detection of biomarkers of acetaminophen toxicity (acetaminophen protein adducts) in clinical samples and their correlation with clinical endpoints.
Dr. Kilts is the founding Director of the Brain Imaging Research Center (BIRC) in the new UAMS Psychiatric Research Institute (PRI) and an Associate Director of the PRI. Dr. Kilts has a long record of NIH-funded research, most recently in the use of in vivo brain functional, molecular and connectivity imaging to explore the neural network processing basis of human behavior. With a focus on drug abuse and addiction, he has a clinical research focus on the use of neuroimaging technology to define the brain basis of psychiatric disorders and their treatment.
Elucidation of biochemical mechanisms involved with kidney damage during sepsis and transplantation. Focus on mitochondria, cell death, and oxidant generation as well as novel therapies to reduce damage.
The Pharmaceutical Evaluation and Policy program investigates the impact pharmaceutical products, policies, and services has on patient and system level outcomes.
My research efforts focus on developing new metabolomic approaches which can help us better understand adverse drug reactions and provide new therapeutic strategies. Currently, we are studying phase I and II metabolism of warfarin and applying this information to clinical applications by trying to understand the relationship between warfarin metabolism and anticoagulant therapy outcomes.
Cell-mediated immunity against human papillomavirus (HPV), HPV therapeutic vaccine development, cancer immunotherapy
Research interests include the phase I and II clinical trials focused primarily on the development of new medications and combinations of medication and behavioral interventions for the treatment of opioid and/or psychostimulant dependence and withdrawal.